Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers
Jiaojiao Ni(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoqing Xu(Zhejiang Chinese Medical University), Yanru Xie(Lishui Central Hospital), Wei Zhuo(Women's Hospital, School of Medicine, Zhejiang University), Jianying Jin(Wenzhou Medical University), Shurui Zhou(Zhejiang Cancer Hospital), Qiuxiang Ou(Genesee Community College), Junrong Yan, Qinhong Zheng(Quzhou City People's Hospital), Junjun Shen(Institute of Materials Research of the Slovak Academy of Sciences), Jingjing Li(Shenyang Ligong University), Chaoqun Li(Zhejiang Cancer Hospital), Qi Xu(Zhejiang Cancer Hospital), Tieming Xie(Zhejiang Cancer Hospital), Qian Yin(Zhejiang Cancer Hospital), Yihui Huang(Zhejiang Chinese Medical University), Wei Wu(Chinese Academy of Sciences), Haiping Zhao(Fuyang City People's Hospital), Xiaoying Wu(Wuhan University), Yan Feng(Anhui Medical University), H. Chen, Yang Shao(Sanya University)
Cited by 7
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412